This trial will assess the safety and efficacy of etrasimod in people with moderate-to-severe UC who have previously received treatment in a double-blind study.
1 Primary · 15 Secondary · Reporting Duration: Up to approximately 5 years
Experimental Treatment
912 Total Participants · 1 Treatment Group
Primary Treatment: Etrasimod · No Placebo Group · Phase 3
Age 16 - 80 · All Participants · 2 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Texas | 100.0% |
18 - 65 | 100.0% |
Texas Digestive Disease Consultants - San Marcos | 100.0% |
Did not meet criteria | 100.0% |